CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

Key facts

Sponsor

New York Medical College

Intervention

CD30 CAR T-cell(biological)

Enrollment

21 enrolled

Eligibility

6-29 years · All sexes

Timeline

2024 – 2040

Study locations (1)

• New York Medical College, Valhalla, New York, United States

Collaborators

University of North Carolina

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT07374068
  Prognostic Model of Elderly Hodgkin Lymphoma in China
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGNCT07356882
  European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE2NCT06848569
  Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
  Sun Yat-sen University
• RECRUITINGPHASE2, PHASE3NCT06563245
  Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
  Children's Cancer Group, China
• RECRUITINGPHASE2NCT04838652
  Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
  University of Cologne
• RECRUITINGPHASE2NCT05900765
  A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
  Sun Yat-sen University
• RECRUITINGNCT06822855
  Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
  Azienda USL Reggio Emilia - IRCCS
• ACTIVE NOT RECRUITINGPHASE1NCT04640779
  Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
  Mayo Clinic

See all trials for Hodgkin lymphoma →